How long before surgery should pioglitazone and Farxiga (dapagliflozin) be stopped?

Perioperative Management of Pioglitazone and Farxiga (Dapagliflozin)

Stop Farxiga (dapagliflozin) at least 3 days before surgery, and pioglitazone can be held on the day of surgery.

SGLT2 Inhibitor (Farxiga/Dapagliflozin) - Critical Timing

Farxiga must be discontinued ≥3 days (72 hours) before scheduled surgery to reduce the risk of perioperative metabolic acidosis and euglycemic diabetic ketoacidosis 1, 2. This is a Class I recommendation from the 2024 AHA/ACC/ACS perioperative cardiovascular management guidelines 1.

Key Evidence for SGLT2 Inhibitor Cessation:

• The FDA drug label for Farxiga explicitly states: "Withhold FARXIGA for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting" 2

• Multiple guidelines consistently recommend 3-4 day cessation 3, 4, 3, 5:

  • Dapagliflozin, empagliflozin, and canagliflozin: stop ≥3 days before surgery
  • Ertugliflozin: stop ≥4 days before surgery

• The 2025 UK multidisciplinary consensus statement supports stopping SGLT2 inhibitors "the day before and the day of a procedure" (minimum 36-52 hours depending on timing) 6, though this is less conservative than US guidelines

Why This Matters - The Ketoacidosis Risk:

SGLT2 inhibitors cause euglycemic diabetic ketoacidosis (euDKA) - a life-threatening condition where patients develop severe metabolic acidosis with ketones but WITHOUT the typical hyperglycemia (glucose may be <250 mg/dL or even <180 mg/dL) 1, 2, 7, 8. This makes diagnosis challenging because:

• Blood glucose appears reassuring
• Classic DKA symptoms (nausea, vomiting, abdominal pain, tachypnea) are nonspecific postoperatively
• The diagnosis is often delayed

Case evidence demonstrates real risk: Multiple case reports document euDKA occurring even when SGLT2 inhibitors were stopped 1-2 days preoperatively 8, and even in non-diabetic patients taking dapagliflozin for heart failure 7. One study showed perioperative DKA risk of 1.02 per 1000 patients on SGLT2 inhibitors versus 0.69 per 1000 not on them 6.

Important Nuances:

For patients on SGLT2 inhibitors for heart failure (not diabetes): The same 3-day cessation rule applies 1, 7. Don't make the mistake of continuing these medications just because they're prescribed for heart failure rather than diabetes - the ketoacidosis risk remains.

Urinary glucose excretion persists for 3 days after stopping 2, and ketoacidosis has been reported lasting >6 days and up to 2 weeks after SGLT2 inhibitor discontinuation 2.

Recent contradictory evidence: A 2025 study of emergency surgery patients found no increased DKA risk with preoperative SGLT2 inhibitor use 9, but this should not change practice for elective surgery where you have time to properly discontinue the medication.

Pioglitazone (Thiazolidinedione) - Less Critical

Pioglitazone should be held on the day of surgery 3, 4, 3, 5. This is the standard approach for oral antidiabetic agents that are not SGLT2 inhibitors.

Key Points for Pioglitazone:

• No specific extended preoperative cessation period is required (unlike SGLT2 inhibitors)
• Hold the morning dose on the day of surgery
• The primary concern is avoiding hypoglycemia perioperatively, not ketoacidosis
• Can be restarted postoperatively once the patient is eating and drinking normally

General Perioperative Diabetes Management Context:

Other medications to hold on day of surgery 3, 4, 3, 5:

• Metformin: hold on day of surgery (not 3 days before)
• Sulfonylureas and meglitinides: hold on day of surgery
• Other oral agents: hold morning of surgery

Blood glucose targets perioperatively: 100-180 mg/dL (some guidelines say 80-180 mg/dL) 3, 4, 3, 5

Practical Algorithm for Your Patient:

1. Count back from surgery date:

   • Farxiga: Last dose should be ≥3 days (72 hours) before surgery
   • Pioglitazone: Last dose the evening before surgery (hold morning dose)

2. Monitor for ketoacidosis risk factors even after stopping Farxiga:

   • Prolonged fasting
   • Dehydration
   • Insulin dose reductions
   • Consider checking ketones if patient develops nausea, vomiting, or unexplained acidosis postoperatively

3. Restart timing postoperatively:

   • Farxiga: Resume when patient is clinically stable and has resumed oral intake 2
   • For inpatients: Consider checking capillary ketones <0.6 mmol/L before restarting 6
   • Pioglitazone: Resume when eating and drinking normally

Common Pitfall to Avoid:

Do not assume SGLT2 inhibitors are safe to continue just because the patient has heart failure rather than diabetes - the ketoacidosis risk applies regardless of indication 7. The 2024 AHA/ACC guidelines specifically address this, recommending 3-4 day cessation for patients with heart failure on SGLT2 inhibitors undergoing noncardiac surgery 1.